What Happens When You Stop Using GLP-1 Medications?
With millions of people relying on injectable GLP-1 medications like Ozempic, Wegovy, or Zepbound, a lingering question arises: what occurs when the injections cease? Earlier clinical trials hinted at an alarming “rebound” effect, indicating that patients often regained a significant amount of lost weight almost immediately after halting treatment.
However, a new study from the Cleveland Clinic, featured in the journal Diabetes, Obesity, and Metabolism, provides a more optimistic view of the situation.
This research analyzed nearly 8,000 adults in Ohio and Florida who used semaglutide or tirzepatide for a duration of three to twelve months before discontinuing. Unlike controlled clinical trials, the researchers aimed to observe “real-world” outcomes, acknowledging that many patients tend to switch from one medication to another.
Interestingly, the study found that overall, patients didn’t experience a significant regain of weight in the year following their cessation of GLP-1 medication. For those treated specifically for obesity, the average weight loss before stopping was 8.4%, and one year later, they had only regained about 0.5% on average.
Lead study author Dr. Hamlet Gasoyan noted, “Our real-world data shows that many patients who stop semaglutide or tirzepatide opt to restart the medication or switch to another obesity treatment. This could explain why they regain less weight compared to patients in randomized trials.”
This suggests that the rebound weight gain seen in clinical settings might stem from patients being left without ongoing support, a situation that doesn’t typically occur in actual healthcare practices. It was estimated that 27% of participants transitioned to different medications, including earlier obesity drugs, while around 20% resumed their original medication after resolving issues with insurance or side effects.
Additionally, 14% engaged in intensive lifestyle modification programs, closely working with dietitians and fitness specialists. Those individuals who managed to maintain their weight often remained actively engaged with the healthcare system, utilizing either alternative prescriptions or structured lifestyle support.
Of course, the study had its limitations. The authors acknowledged that the participants were drawn from a single, large integrated health system in Ohio and Florida. This particularity in patient characteristics and healthcare delivery may limit how widely applicable the findings are across the U.S.
Some weight reduction recorded might also relate to other interventions that the research team couldn’t entirely capture. Dr. Gasoyan mentioned future efforts will focus on examining the effectiveness of different treatment options for obesity for patients who discontinue their GLP-1 medications, ultimately assisting individuals and their healthcare providers in making informed choices.
